RADX Radiopharm Theranostics Limited American Depositary Shares Pharmaceutical Preparations Best Pharmaceutical Stocks 2026 →

Radiopharm Theranostics (RADX) Stock: Buy, Sell, or Hold?

$0.63
-0.04 (-6.33%) ▼
5d: -17.05% 30d: -33.64% 90d: -74.16%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (53%)
Quality Score
39/100
Position
OVERSOLD
30-Day Fair Range
$0.77 – $1.04
Position: OVERSOLD
Forward P/E & Valuation
-0.2x
Next 12M consensus est.
Wall Street Target
$16.29
+2484.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$0.63 / $0.96
Trend: Strong Downtrend
💡Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
⏸️ WAIT FOR STABILIZATION: RADX is down 17.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.

Get Alerted When RADX Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

In-depth Analysis How we analyze

Valuation Analysis: RADX is currently trading at $0.63, which is considered oversold relative to its 30-day fair value range of $0.77 to $1.04.

Technical Outlook: Technically, RADX is in a strong downtrend. The price is currently testing key support at $0.63. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.3% recently.

Market Sentiment: RADX scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $16.29 (+2484.6%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position OVERSOLD
Historical Trading Range $0.77 - $1.04
Company Quality Score 39/100 (SELL)
Volume Confirmation HIGH
Confidence Score 52.6%

Trading Range & Key Levels

30-Day Trading Range $0.77 - $1.04
Current vs Trading Range OVERSOLD
Support Level $0.63
Resistance Level $0.96
Current Trend Strong Downtrend
Technical data as of Nov 20, 2026

Quantitative Signal Breakdown

  • BULLISH: Price oversold vs 30-day range
  • BEARISH: Weak technical setup (25/100)
  • BULLISH: High volume confirmation
  • BEARISH: Downward momentum (-6.3%)
  • BULLISH: Trading 2484.6% below Wall St target ($16.29)
  • WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market

Fundamental Context

Forward P/E (Next Year Est.) -0.20
Wall Street Target $16.29 (+2484.6%)
Revenue Growth (YoY) -36.9%
Share RADX Analysis

Share this live RADX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.

bloggers & journalists: you are free to use our charts with attribution.
Last updated: November 22, 2026 5:06 AM ET
Data refreshes hourly during market hours. Next update: 6:06 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for RADX.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
ARGX
argenx NV ADR
STRONG BUY
24 analysts
$1147 50 HOLD
KYMR
Kymera Therapeutics Inc
STRONG BUY
24 analysts
$145 37 SELL
DNTH
Dianthus Therapeutics In…
STRONG BUY
18 analysts
$139 44 HOLD
IRD
Opus Genetics, Inc.
STRONG BUY
17 analysts
$14 47 HOLD
SYRE
Spyre Therapeutics Inc.
STRONG BUY
18 analysts
$124 42 HOLD
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals